SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
154.40    1.60 (1.05%)
Bid:
154.40
Ask:
154.80
Spread: 0.40 (0.259%)
Market Cap: £883.65m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Interim Management Statement

25 Oct 2013 07:00

RNS Number : 3576R
Elementis PLC
25 October 2013
 



 

 

Elementis - Interim Management Statement

 

Elementis plc (ELM.L, "Elementis" or "the Group"), the Global Specialty Chemicals Company, today issues its Interim Management Statement for the three months ended 30 September 2013.

 

Commenting on the Group's performance Group Chief Executive, David Dutro, said:

"Elementis is pleased to report another resilient performance in spite of an economic background where growth is turning out to be slower than generally anticipated. The Group's strategy of creating its own growth opportunities, combined with its strong, diverse market positions and a return to more normal trading patterns in oilfield drilling are the key drivers of the Group's 12 per cent sales growth in the current quarter, compared to the same period last year. The integration of the Group's two recent acquisitions, Watercryl in Brazil and Hi-Mar in the US, is progressing well and the second and final phase of our new coatings additives plant in North America is well underway. These investments strengthen the broad geographic presence and enhance the Group's exciting market positions and will support further growth over the medium term."

 

 

Specialty Products sales improved by 15 per cent, or 8 per cent excluding acquisitions and currency.

 

· In coatings, sales in North America were higher by 12 per cent, mainly due to the acquisition of Hi-Mar earlier in the year. In Asia Pacific, sales increased by 11 per cent as the business continued to benefit from its market position in China, experiencing strong demand from local high-end industrial markets. Latin American sales increased by 68 per cent, driven by the acquisition of Watercryl in September 2012, and good progress is being made in expanding Watercryl sales outside of Brazil. In Europe, underlying economic conditions continue to be subdued as headline sales improved by 3 per cent, with currency contributing 4 per cent.

 

· In personal care, the business continued to benefit from the initiatives of a refocused management structure, with additional resources in new geographies and new product launches. As a result, sales improved by 16 per cent or 13 per cent excluding currency.

 

· Sales to the oil and gas drilling sector continued to demonstrate a sustained recovery following the impact of industry destocking in the latter part of 2012, maintaining the robust pace reported for the first six months of the year. Consequently, sales to this sector were at a similar level to the average quarterly sales in the first half of this year and 35 per cent ahead of the same period last year.

 

· Operating margin in the third quarter was similar to that reported for the first six months of the year as overall pricing and contribution margins remained stable.

 

As expected, following the planned maintenance shutdown in the early part of the year, Chromium trading patterns in the current quarter returned to more normal levels. Chromium sales in the quarter were 5 per cent ahead of the same period last year and at a similar level to the second quarter of the current year. As production volumes and plant utilisation returned to more normal levels, margins improved compared to the first half of the year and operating margin for the full year is expected to be in the range of 24-26 per cent. Consistent with our strategy of stable earnings and cash flow, we expect the performance of Chromium in the second half of 2013 will be similar to the second half of last year.

 

Cash flow continues to be a positive aspect of the Group's performance and it is anticipated that the end of year balance sheet will show a net cash balance of at least $30 million.

 

Overall we remain confident in the Group's ability to deliver growth that is in excess of the underlying economies in which it operates and expect our full year earnings per share to be in line with market expectations.

 

 

 

 

 

Enquiries:

Elementis + 44 (0) 207 408 9300

Brian Taylorson, Finance Director

  

FTI Consulting

 + 44 (0) 207 831 3113

Deborah Scott

Matthew Cole

  

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUSOVROUARUAA
Date   Source Headline
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights
31st Jan 20233:04 pmRNSSale of Chromium business
19th Jan 20237:00 amRNSTrading Update
3rd Jan 20239:47 amRNSTotal Voting Rights
8th Dec 20222:10 pmRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSSale of Chromium business
23rd Nov 20223:54 pmRNSHolding(s) in Company
16th Nov 20221:43 pmRNSHolding(s) in Company
10th Nov 20229:40 amRNSHolding(s) in Company
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20229:48 amRNSTotal Voting Rights
31st Oct 20223:23 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSQ3 Trading Update
18th Oct 20223:13 pmRNSHolding(s) in Company
3rd Oct 20229:39 amRNSTotal Voting Rights
29th Sep 202212:45 pmRNSDirector/PDMR Shareholding
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
22nd Sep 202211:17 amRNSDirector/PDMR Shareholding
21st Sep 20224:58 pmRNSDirector/PDMR Shareholding
21st Sep 20223:48 pmRNSDirector/PDMR Shareholding
6th Sep 202212:52 pmRNSDirector Declaration
5th Sep 20224:14 pmRNSAdditional Listing
1st Sep 202212:39 pmRNSHolding(s) in Company
1st Sep 20229:15 amRNSBlock listing Interim Review
1st Sep 20229:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.